The U.S. Food and Drug Administration has granted accelerated approval to Forzinity (elamipretide) injection as the first ...

Dr. Lerman's Renovascular Research Lab at Mayo Clinic studies ways to improve atherosclerotic renal artery stenosis, ...

FDA approves Stealth Biotherapeutics' Forzinity injection for rare genetic disease Barth syndrome, impacting males, with ...

They derive their energy from differences in the concentration of hydrogen ions across some of these membranes ...

First-of-its-kind therapy developed by Johns Hopkins researchers cleared for treatment of Barth syndrome, a condition that ...

Explore what FDA approval of elamipretide means for ultra-rare disease drug development and the outlook for future biotech ...

A new study reports that prenatal exposure to the insecticide chlorpyrifos is associated with lasting changes in the ...

The FDA has granted accelerated approval for the elamipretide injection, the first treatment for Barth syndrome in patients weighing at least 30 ...

Researchers from the Freunberger group at the Institute of Science and Technology Austria (ISTA) have unveiled pivotal ...

Higher activity of PGC-1α enables brown fat cells in females to achieve thermogenic activity and energy expenditure compared to males, reveals a study conducted in Japan. This research demonstrates ...

Stealth BioTherapeutics has claimed FDA approval for Forzinity, the first treatment for ultra-rare disease Barth syndrome, ...